Organoid Models of Tumor Immunology

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2020 Jul 14

PMID 32654925

Citations 173

Authors

Kanako Yuki

Ning Cheng

Michitaka Nakano

Calvin J Kuo

Affiliations

Soon will be listed here.

Abstract

Cellular interactions in the tumor microenvironment (TME) significantly govern cancer progression and drug response. The efficacy of clinical immunotherapies has fostered an exponential interest in the tumor immune microenvironment, which in turn has engendered a pressing need for robust experimental systems modeling patient-specific tumor-immune interactions. Traditional 2D in vitro tumor immunotherapy models have reconstituted immortalized cancer cell lines with immune components, often from peripheral blood. However, newly developed 3D in vitro organoid culture methods now allow the routine culture of primary human tumor biopsies and increasingly incorporate immune components. Here, we present a viewpoint on recent advances, and propose translational applications of tumor organoids for immuno-oncology research, immunotherapy modeling, and precision medicine.

Citing Articles

Adapting systems biology to address the complexity of human disease in the single-cell era.

Fischer D, Villanueva M, Winter P, Shalek A Nat Rev Genet. 2025; .

PMID: 40065155 DOI: 10.1038/s41576-025-00821-6.

Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing.

Chen P, Zhou J, Chu X, Feng Y, Zeng Q, Lei J Bioact Mater. 2025; 46:582-596.

PMID: 40061435 PMC: 11889390. DOI: 10.1016/j.bioactmat.2024.09.008.

Genomic and micro-environmental insights into drug resistance in colorectal cancer liver metastases.

Kuang J, Li J, Zhou S, Li Y, Lin J, Huang W Discov Oncol. 2025; 16(1):241.

PMID: 40009285 PMC: 11865409. DOI: 10.1007/s12672-025-01976-8.

A promising breakthrough in pancreatic cancer research: The potential of spheroids as 3D models.

Jamshidi N, Jamshidi N, Modarresi Chahardehi A, Shams E, Chaleshi V Bioimpacts. 2025; 15:30241.

PMID: 39963557 PMC: 11830132. DOI: 10.34172/bi.30241.

Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses.

Turpin R, Peltonen K, Rannikko J, Liu R, Kumari A, Nicorici D Oncoimmunology. 2025; 14(1):2466305.

PMID: 39960413 PMC: 11834457. DOI: 10.1080/2162402X.2025.2466305.

References

Mo X, Tang C, Niu Q, Ma T, Du Y, Fu H . HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers. Cell Chem Biol. 2019; 26(3):331-339.e3. PMC: 6501824. DOI: 10.1016/j.chembiol.2018.11.011. View

Chakrabarti J, Holokai L, Syu L, Steele N, Chang J, Wang J . Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget. 2019; 9(100):37439-37457. PMC: 6324774. DOI: 10.18632/oncotarget.26473. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Yan H, Siu H, Law S, Ho S, Yue S, Tsui W . A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell. 2018; 23(6):882-897.e11. DOI: 10.1016/j.stem.2018.09.016. View

Hammerl D, Rieder D, Martens J, Trajanoski Z, Debets R . Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies. Trends Immunol. 2018; 39(11):921-936. DOI: 10.1016/j.it.2018.09.004. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

10.

Sontheimer-Phelps A, Hassell B, Ingber D . Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019; 19(2):65-81. DOI: 10.1038/s41568-018-0104-6. View

11.

Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K . Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018; 173(2):515-528.e17. PMC: 5890941. DOI: 10.1016/j.cell.2018.03.017. View

12.

Biffi G, Oni T, Spielman B, Hao Y, Elyada E, Park Y . IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2018; 9(2):282-301. PMC: 6368881. DOI: 10.1158/2159-8290.CD-18-0710. View

13.

Sung P, Rama N, Imbach J, Fiore S, Ducarouge B, Neves D . Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity. Cancer Res. 2019; 79(14):3651-3661. DOI: 10.1158/0008-5472.CAN-18-2952. View

14.

DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N . CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16(2):91-102. PMC: 2778576. DOI: 10.1016/j.ccr.2009.06.018. View

15.

Ostrand-Rosenberg S, Fenselau C . Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. J Immunol. 2018; 200(2):422-431. PMC: 5765878. DOI: 10.4049/jimmunol.1701019. View

16.

Sato T, Vries R, Snippert H, van de Wetering M, Barker N, Stange D . Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459(7244):262-5. DOI: 10.1038/nature07935. View

17.

De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid M . Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021; 10. PMC: 8384419. DOI: 10.7554/eLife.60747. View

18.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

19.

Beshiri M, Tice C, Tran C, Nguyen H, Sowalsky A, Agarwal S . A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res. 2018; 24(17):4332-4345. PMC: 6125202. DOI: 10.1158/1078-0432.CCR-18-0409. View

20.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View